Trim 30-35% of MDT on rally into $92.00-$93.50 zone; retain 65-70% core position for dividend carry amid confirmed technical deterioration
The Underweight call synthesizes conservative analyst trim sizing with neutral analyst's tighter entry zone refinement, validated by the binding 9/10 lesson that pure dividend-carry patience through fading momentum has already bled 1.6% alpha in the most recent window. Technical deterioration is confirmed with 50 SMA ($87.69) below 200 SMA ($88.55), MACD histogram more than doubled in negativity (-0.07 to -0.40 in 10 sessions), and price below both 10 EMA and VWAP. The 13.7% headline Q1 FY27 growth is flattered by ~5.8pp calendar noise; the +57.6% EPS growth is mean-reversion accounting from a depressed base (reversing ~$280M in charges), not structural expansion. The 14.2x forward P/E embeds ~57% EPS recovery that the normalized 7.9% organic growth does not justify standalone. The $43B goodwill against negative tangible book creates real impairment tail risk from active $1.162B Q1 acquisition integration (Hugo/Affera). MDT is a competitive follower (Edwards owns TAVR, BSX/J&J own PFA, ISRG owns robotics), making deal spend catch-up investment rather than pipeline strength. Core exposure retained because fundamentals are genuinely constructive (49 consecutive dividend raises, 1.4x quarterly FCF coverage, cardiovascular re-acceleration, MiniMed spin validating strategic clarity), but the over-extension must be trimmed ahead of asymmetric hawkish FOMC window (80% hike odds).
| Position | Action |
|---|---|
| Price rallies into $92.00-$93.50 zone (20 SMA pivot to midpoint between 10 EMA and upper Bollinger) | Trim 30-35% of MDT exposure |
| Price reaches $95.00 | Hard abort - do not trim further |
| Price weakness to $88.55 | Do NOT add - that level is a breakdown threshold where confirmed close below 200 SMA opens path to $78.66 (13% additional downside) |
| Retain core position through macro window | Hold 65-70% position sized to 3.14% dividend carry |
Medtronic represents a rare combination of accelerating fundamental growth (13.7% organic), raised guidance, and a deeply discounted valuation (14.2x forward P/E) in a macro environment specifically designed to favor defensive dividend growers with quality compound profiles.
| Indicator | Value | Signal |
|---|---|---|
| Close | 90.96 | neutral |
| 10 EMA | 91.88 | bearish |
| 50 SMA | 87.69 | bullish |
| 200 SMA | 88.55 | bullish |
| MACD Line | 1.17 | bearish |
| MACD Signal | 1.57 | bearish |
| MACD Histogram | -0.40 | bearish |
| RSI (14) | 51.62 | neutral |
| Bollinger Upper Band | 94.27 | neutral |
| Bollinger Middle Band (20 SMA) | 92.00 | neutral |
| Bollinger Lower Band |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Price reaches $95.00
Then: Abort trimming - protect against adding into confirmed strength
Medtronic trades at a significant valuation discount to peers while offering superior growth, making it the cheapest growth re-rating candidate in S&P 500 healthcare
↩ rebuts: “Bear MACD analysis measures momentum over 8 days; forward P/E measures earnings power over 8 quarters”
EV: Target $103–$104 (prior 52-week high / overhead supply zone); Upper Bollinger Band target $94.27 · concedes: Short-term technical weakness is real (MACD bearish crossover, price below 10 EMA, inside-day reversal) — but these indicators lag earnings by definition and don't account for the fundamental reset; A retest of the $88.55–$89.73 zone (200 SMA / lower Bollinger Band convergence) is possible and would be a buying opportunity, not a breakdown signal; The HOLD recommendation is a non-call with embedded bull cases (coiled spring, golden cross forming); Peer valuation multiples (25-40x) may be justified by higher growth profiles, though MDT's 13.7% organic growth challenges that assumption
Medtronic is a value trap disguised as a dividend yield opportunity—the headline growth numbers are calendar-flattered accounting noise, the technical structure is a confirmed death cross, and $43B in goodwill against negative tangible book value creates structural impairment risk that the bull's thesis ignores entirely.
· concedes: Underlying ~7.9% organic growth is still solid mid-single-digit performance; Dividend yield of 3% is real income while waiting; MiniMed standalone is showing +15.8% revenue growth; Some recent acquisitions (Affera) may provide pipeline fuel; Q2 FY27 may see continued momentum if restructuring tailwinds materialize
→ vs conservative: Stripping out calendar noise benefit to call growth 'just 7.9%' is mental accounting that misses the turnaround; 7.9% organic growth for a 116 billion dollar mega-cap is exceptional, not 'solid but priced in'
→ vs conservative: Calling Medtronic a 'competitive follower' is lazy analysis; MDT owns structural heart globally, has Hugo platform ramping, Affera acquisition advancing PFA, and MiniMed spin off validating strategic clarity with 15.8% standalone revenue growth; cardiovascular segment is outgrowing rest of med tech per Wells Fargo commentary
→ vs conservative: Goodwill concern (43 billion) must be weighed against cash generation (5.4B TTM FCF, 4.7% yield) and operational strength; paper impairment only matters if operational deterioration occurs, and Q1 beat-and-raise plus raised guidance indicates the opposite
→ vs conservative: Macro risk is not MDT risk; in hawkish non-recessionary regimes (7% recession odds) dividend-paying value names outperform; reading macro risk as MDT risk is错误的
→ vs neutral: Waiting for resolution above 92.30 or below 89.73 is mediocrity; sitting on hands with 14.2x forward P/E, 57.6% projected EPS growth, and 3% dividend yield leaves alpha on the table
→ vs aggressive: Trader calling 88.55 a 'death cross template' and 'breakdown level not a buying opportunity' is reading the chart with confirmation bias toward bearishness; price is above both moving averages and 88.55 is exactly where you ADD, not trim
→ vs aggressive: Trader's plan to trim 25 to 40 percent on rally into 92.30 to 94.17 is selling into demand at the moment when bullish fundamentals are being confirmed by price action approaching resistance
| 89.73 |
| neutral |
| ATR (14) | 2.28 | neutral |
| VWMA (~30-period) | 92.08 | bearish |
| Volume | 5,405,667 | neutral |
Support: 89.73 · 88.55 · 87.69 · 78.66 | Resistance: 91.88 · 92 · 92.08 · 94.17 · 94.27 · 103.76
MDT exhibits a neutral technical setup with conflicting signals. Primary trend remains constructive as price holds above both the 50 SMA (87.69) and 200 SMA (88.55), though the long-term moving average stack is not yet a clean bullish alignment (50 SMA still below 200 SMA). Short-term momentum has shifted bearish with price below the 10 EMA and VWMA, confirmed by MACD crossover with histogram deepening to -0.40. Bollinger Bands are compressing (upper 94.27, lower 89.73) with price in the lower half, suggesting a coiled-spring setup ahead of directional expansion. RSI neutral at 51.62 leaves room for either direction without entering overbought or oversold territory. Critical support sits at the 200 SMA (88.55) while key resistance is the 10 EMA/VWMA cluster at 91.88-92.08, with a decisive break above 92.30 or below 89.73 to confirm next directional move.
Market Cap
$116.35B
Share Price (approx.)
~$90.95
52-Week High
$106.33
52-Week Low
$73.31
50-Day MA
$87.45
200-Day MA
$89.60
Beta
0.574
PE (TTM)
22.40x
Forward PE
14.21x
PEG Ratio
1.65
P/B
2.32x
EPS (TTM)
$4.06
Forward EPS
$6.40
Dividend Yield
3.14%
Revenue TTM
$37.54B
Revenue Q1 FY27
$9,756M
Revenue Q4 FY26
$9,807M
Revenue Q3 FY26
$9,017M
Revenue Q2 FY26
$8,961M
Revenue Q1 FY26
$8,578M
Gross Profit Q1 FY27
$6,340M
Operating Income Q1 FY27
$1,836M
Net Income Q1 FY27
$1,470M
Diluted EPS Q1 FY27
$1.14
Diluted EPS Q4 FY26
$0.96
Diluted EPS Q3 FY26
$0.89
Diluted EPS Q2 FY26
$1.07
Diluted EPS Q1 FY26
$0.81
Gross Margin
65.3%
Operating Margin
19.3%
EBITDA
$10,408M
Net Profit Margin
13.9%
R&D Spend
~$11.6B annualized
Total Assets
$93,306M
Total Assets Jul-25
$90,972M
Cash & ST Investments
$8,819M
Receivables
$6,357M
Inventory
$6,215M
Goodwill & Intangibles
$53,424M
Goodwill
$43,187M
Net PP&E
$7,473M
Non-current Accounts Receivable
$3,703M
Total Liabilities
$42,456M
Total Debt
$28,153M
Net Debt
$26,410M
Pension/OPEB Current
$1,906M
Payables & Accrued
$7,357M
Stockholders' Equity
$50,232M
Common Stock Outstanding
1,280.05M shares
Book Value per Share
$39.24
Current Ratio
2.07x
Debt/Equity
55.4% (0.55x)
Invested Capital
$78,333M
Tangible Book Value
($3,192)M
Working Capital
$12,591M
Operating Cash Flow Q1 FY27
$1,793M
Operating Cash Flow Q4 FY26
$2,573M
Operating Cash Flow Q3 FY26
$2,744M
Operating Cash Flow Q2 FY26
$925M
Operating Cash Flow Q1 FY26
$1,088M
CapEx Q1 FY27
($503)M
CapEx Q4 FY26
($488)M
Free Cash Flow Q1 FY27
$1,290M
Free Cash Flow Q4 FY26
$2,085M
Free Cash Flow Q3 FY26
$2,300M
Free Cash Flow Q2 FY26
$457M
Free Cash Flow Q1 FY26
$584M
TTM Free Cash Flow
~$5,412M
Cash Dividends Paid Q1 FY27
($921)M
Cash Dividends Paid Quarterly
~$910M
Acquisitions Q1 FY27
($1,162)M
Share Repurchases Q1 FY27
($267)M
Net Income TTM
$5.23B
Net Debt/EBITDA
~2.5x
ROE
10.6%
ROA
5.1%
Strengths
Concerns
Medtronic trades at a discounted forward P/E of 14.2x with a recovery story embedded in consensus estimates projecting 57.6% EPS growth (TTM $4.06 to forward $6.40). The company generates robust FCF of $5.4B TTM (4.7% yield), maintains strong 65.3% gross margins, and pays a 3.14% dividend well-covered by cash flow. Key risks include negative tangible book value, high goodwill ($43.2B), restructuring charges rolling off, and execution uncertainty on new product cycles including Hugo robotics and Affera pulsed-field ablation.